Alnylam Pharmaceuticals, Inc.

Please stand by. Your program is about to begin. If you need assistance during your conference today, please press star zero. Good day, everyone, and welcome to today's Nylon Pharmaceuticals Q3 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing the star and 1 on your telephone keypad. You may withdraw yourself from the queue by pressing star 2. Please note this call is being recorded, and I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to the company.

Good morning. I'm Christine Lindenboom, Chief Corporate Communications Officer at LNILAM. With me today are Yvonne Greenstreet, Chief Executive Officer, Tolga Tanguilar, Chief Commercial Officer, Krishkal Garg, Chief Financial Officer, and Jeff Fulton, Chief Financial Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the events section of the investors page of our website, investors.lnlm.com slash events. During today's call, as outlined in slide two, Yvonne will offer introductory remarks and provide some general context. we'll provide an update on our global commercial progress, which will review pipeline updates and clinical progress, and Jeff will review financials and guidance, followed by a summary of upcoming milestones before we open the call for your questions. I would like to remind you that this call will contain remarks concerning L9's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent periodic report on file with the SEC. In addition, any forward-looking statements represent our views only as of the date of this recording and should not be relied upon as we're representing our views as of any subsequent date. We specifically explain any obligation to update such statements. With that, I'd like to turn this over to Yvonne. Yvonne?

Thanks, Christine, and thank you, everyone, for joining the call today. The third quarter of 2024 marked a period of continued progress for Alnylam on all fronts. Commercially, we achieved 34% year-over-year growth in global net product revenue, generating $420 million across our four marketed products. We made great progress with our TCR franchise, sharing additional results from the helios b study of retreat ram and filing regulatory submissions in the us and eu we also hosted a ttr investor day to highlight our preparations in anticipation of a potential launch in attr cardiomyopathy next year we believe that ambutra and our broader ttr portfolio will serve as our flagship franchise similar in potential impact to what ilia has been for regeneron or what the cystic fibrosis franchise has been for Vertex, delivering to those companies durable growth and enabling those companies to invest in R&D, new product development, and portfolio diversification for the long term. Lastly, our early pipeline saw continued momentum as well, particularly our efforts in CNF. We initiated a phase one study of ALN-HTTO2 in Huntington's disease, And we're pleased to announce today initial results from the multi-dose portion of the phase one study of Mibeltoran in patients with early-onset Alzheimer's disease. These results are encouraging for our CNS platform as they provide early evidence that multiple doses of an intrathecally-administered siRNA are well-tolerated. We're continuing to progress towards achievement by year-end 2025 of our nylon pizza fifth by 25 goals. and are steadfast in our belief that we're on track to become a top tier biotech, developing and commercializing transformative medicines for patients around the world with rare and prevalent diseases driven by a high yielding pipeline of first and or best in class product candidates from our organic product engine, all while delivering strong financial results. With that, let me now turn the call over to Tolga for a review of our commercial performance. Tolga,